Validive (clonidine HCl MBT)
Prevention of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapy
Key Facts
Indication
Prevention of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapy
Phase
Phase 2b/3
Status
Active; Phase 2b completed
Company
About Monopar Therapeutics
Monopar Therapeutics is a publicly traded biotech company (NASDAQ: MNPR) advancing a pipeline of novel oncology candidates. Its most advanced asset, Validive (clonidine HCl mucoadhesive buccal tablet), is designed to prevent a debilitating side effect of cancer treatment and has received Fast Track and Orphan Drug designations from the FDA. The company's strategy centers on developing targeted therapies for underserved oncology indications with high unmet medical need.
View full company profile